Login to Your Account

Pharma: Clinic Roundup

Tuesday, September 11, 2012
• Merck & Co. Inc., of Whitehouse Station, N.J., reported data from the two-month discontinuation phase of its 12-month study showing that patients who stopped taking insomnia drug suvorexant, following daily use for one year, experienced a return of their sleeping difficulties similar to those who received placebo, while adverse events were generally consistent with those reported during the 12-month study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription